BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 16941491)

  • 1. Unique substitution of CHEK2 and TP53 mutations implicated in primary prostate tumors and cancer cell lines.
    Zheng L; Wang F; Qian C; Neumann RM; Cheville JC; Tindall DJ; Liu W
    Hum Mutat; 2006 Oct; 27(10):1062-3. PubMed ID: 16941491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational analysis of TP53 and p21 in familial and sporadic ovarian cancer in Japan.
    Amikura T; Sekine M; Hirai Y; Fujimoto S; Hatae M; Kobayashi I; Fujii T; Nagata I; Ushijima K; Obata K; Suzuki M; Yoshinaga M; Umesaki N; Satoh S; Enomoto T; Motoyama S; Nishino K; Haino K; Tanaka K;
    Gynecol Oncol; 2006 Feb; 100(2):365-71. PubMed ID: 16337994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of CHEK2 mutations in prostate cancer.
    Wu X; Dong X; Liu W; Chen J
    Hum Mutat; 2006 Aug; 27(8):742-7. PubMed ID: 16835864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
    Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
    Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
    Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
    Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Truncating variants in p53AIP1 disrupting DNA damage-induced apoptosis are associated with prostate cancer risk.
    Wang X; Wang F; Taniguchi K; Seelan RS; Wang L; Zarfas KE; McDonnell SK; Qian C; Pan K; Lu Y; Shridhar V; Couch FJ; Tindall DJ; Beebe-Dimmer JL; Cooney KA; Isaacs WB; Jacobsen SJ; Schaid DJ; Thibodeau SN; Liu W
    Cancer Res; 2006 Nov; 66(21):10302-7. PubMed ID: 17079449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area.
    Eachkoti R; Hussain I; Afroze D; Aejazaziz S; Jan M; Shah ZA; Das BC; Siddiqi MA
    Cancer Lett; 2007 Apr; 248(2):308-20. PubMed ID: 16996204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer.
    Bleeker WA; Hayes VM; Karrenbeld A; Hofstra RM; Hermans J; Buys CC; Plukker JT
    Am J Gastroenterol; 2000 Oct; 95(10):2953-7. PubMed ID: 11051374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deleterious CHEK2 1100delC and L303X mutants identified among 38 human breast cancer cell lines.
    Wasielewski M; Hanifi-Moghaddam P; Hollestelle A; Merajver SD; van den Ouweland A; Klijn JG; Ethier SP; Schutte M
    Breast Cancer Res Treat; 2009 Jan; 113(2):285-91. PubMed ID: 18297428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases.
    Stapleton AM; Timme TL; Gousse AE; Li QF; Tobon AA; Kattan MW; Slawin KM; Wheeler TM; Scardino PT; Thompson TC
    Clin Cancer Res; 1997 Aug; 3(8):1389-97. PubMed ID: 9815823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High resolution melting for mutation scanning of TP53 exons 5-8.
    Krypuy M; Ahmed AA; Etemadmoghadam D; Hyland SJ; ; DeFazio A; Fox SB; Brenton JD; Bowtell DD; Dobrovic A
    BMC Cancer; 2007 Aug; 7():168. PubMed ID: 17764544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
    Olivier M; Langerød A; Carrieri P; Bergh J; Klaar S; Eyfjord J; Theillet C; Rodriguez C; Lidereau R; Bièche I; Varley J; Bignon Y; Uhrhammer N; Winqvist R; Jukkola-Vuorinen A; Niederacher D; Kato S; Ishioka C; Hainaut P; Børresen-Dale AL
    Clin Cancer Res; 2006 Feb; 12(4):1157-67. PubMed ID: 16489069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Number of somatic mutations in the mitochondrial D-loop region indicates poor prognosis in breast cancer, independent of TP53 mutation.
    Kuo SJ; Chen M; Ma GC; Chen ST; Chang SP; Lin WY; Chen YC; Lee TH; Lin TT; Liu CS
    Cancer Genet Cytogenet; 2010 Sep; 201(2):94-101. PubMed ID: 20682393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.
    Achatz MI; Olivier M; Le Calvez F; Martel-Planche G; Lopes A; Rossi BM; Ashton-Prolla P; Giugliani R; Palmero EI; Vargas FR; Da Rocha JC; Vettore AL; Hainaut P
    Cancer Lett; 2007 Jan; 245(1-2):96-102. PubMed ID: 16494995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Truncating mutations in the ACVR2 gene attenuates activin signaling in prostate cancer cells.
    Rossi MR; Ionov Y; Bakin AV; Cowell JK
    Cancer Genet Cytogenet; 2005 Dec; 163(2):123-9. PubMed ID: 16337854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles.
    Isaacs WB; Carter BS; Ewing CM
    Cancer Res; 1991 Sep; 51(17):4716-20. PubMed ID: 1873816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular heterogeneity in prostate cancer: can TP53 mutation unravel tumorigenesis?
    Roy-Burman P; Zheng J; Miller GJ
    Mol Med Today; 1997 Nov; 3(11):476-82. PubMed ID: 9430782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.
    Petitjean A; Mathe E; Kato S; Ishioka C; Tavtigian SV; Hainaut P; Olivier M
    Hum Mutat; 2007 Jun; 28(6):622-9. PubMed ID: 17311302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
    Russo A; Bazan V; Iacopetta B; Kerr D; Soussi T; Gebbia N;
    J Clin Oncol; 2005 Oct; 23(30):7518-28. PubMed ID: 16172461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 mutation in prostate needle biopsies--comparison with patients follow-up.
    Ecke TH; Schlechte HH; Hübsch A; Lenk SV; Schiemenz K; Rudolph BD; Miller K
    Anticancer Res; 2007; 27(6B):4143-8. PubMed ID: 18225585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.